TipRanks
Hanx Biopharmaceuticals (Wuhan) Co. Ltd. Class H (HK:3378)
:3378
Hong Kong Market
3378
Hanx Biopharmaceuticals (Wuhan) Co. Ltd. Class H
RESEARCH TOOLSreports

Hanx Biopharmaceuticals (Wuhan) Co. Ltd. Class H (3378) Ratios

― Followers

Hanx Biopharmaceuticals (Wuhan) Co. Ltd. Class H Ratios

HK:3378's free cash flow for Q2 2019 was ¥―. For the 2019 fiscal year, HK:3378's free cash flow was decreased by ¥ and operating cash flow was ¥―. See a summary of the company’s cash flow.
Ratios
TTM
Dec 21Dec 20Dec 19Dec 18
Liquidity Ratios
Current Ratio
 0.69-- ― ―
Quick Ratio
 0.53-- ― ―
Cash Ratio
 0.26-- ― ―
Solvency Ratio
 0.05-- ― ―
Operating Cash Flow Ratio
 0.17-- ― ―
Short-Term Operating Cash Flow Coverage
 0.23-- ― ―
Net Current Asset Value
¥ -7.84B¥ -7.84B¥ -4.16B¥ ―¥ ―
Leverage Ratios
Debt-to-Assets Ratio
 0.45-- ― ―
Debt-to-Equity Ratio
 2.04-- ― ―
Debt-to-Capital Ratio
 0.67-- ― ―
Long-Term Debt-to-Capital Ratio
 0.39-- ― ―
Financial Leverage Ratio
 4.50-- ― ―
Debt Service Coverage Ratio
 0.13-- ― ―
Interest Coverage Ratio
 3.92-- ― ―
Debt to Market Cap
 3.66-- ― ―
Interest Debt Per Share
 4.51-- ― ―
Net Debt to EBITDA
 6.99 9.64 3.62 ― ―
Profitability Margins
Gross Profit Margin
5.35%--――
EBIT Margin
5.02%--――
EBITDA Margin
5.02%--――
Operating Profit Margin
4.68%--――
Pretax Profit Margin
3.83%--――
Net Profit Margin
2.99%--――
Continuous Operations Profit Margin
2.99%--――
Net Income Per EBT
78.18%--――
EBT Per EBIT
81.90%--――
Return on Assets (ROA)
2.91%2.91%2.57%――
Return on Equity (ROE)
13.13%13.07%10.57%――
Return on Capital Employed (ROCE)
8.03%8.03%5.49%――
Return on Invested Capital (ROIC)
4.06%4.06%2.78%――
Return on Tangible Assets
2.91%2.91%3.08%――
Earnings Yield
1.15%2.01%1.56%――
Efficiency Ratios
Receivables Turnover
 0.00-- ― ―
Payables Turnover
 13.58-- ― ―
Inventory Turnover
 12.98-- ― ―
Fixed Asset Turnover
 1.47-- ― ―
Asset Turnover
 0.97-- ― ―
Working Capital Turnover Ratio
 -8.22-- ― ―
Cash Conversion Cycle
 1.24 1.24 -5.20 ― ―
Days of Sales Outstanding
 0.00 0.00 0.00 ― ―
Days of Inventory Outstanding
 28.11 28.11 33.92 ― ―
Days of Payables Outstanding
 26.87 26.87 39.12 ― ―
Operating Cycle
 28.11 28.11 33.92 ― ―
Cash Flow Ratios
Operating Cash Flow Per Share
 0.70-- ― ―
Free Cash Flow Per Share
 0.70-- ― ―
CapEx Per Share
 0.00-- ― ―
Free Cash Flow to Operating Cash Flow
 1.00-- ― ―
Dividend Paid and CapEx Coverage Ratio
 0.00-- ― ―
Capital Expenditure Coverage Ratio
 0.00-- ― ―
Operating Cash Flow Coverage Ratio
 0.16-- ― ―
Operating Cash Flow to Sales Ratio
 0.07-- ― ―
Free Cash Flow Yield
58.32%5.03%2.20%――
Valuation Ratios
Price-to-Earnings (P/E) Ratio
 87.13-- ― ―
Price-to-Sales (P/S) Ratio
 0.13-- ― ―
Price-to-Book (P/B) Ratio
 11.30-- ― ―
Price-to-Free Cash Flow (P/FCF) Ratio
 1.70-- ― ―
Price-to-Operating Cash Flow Ratio
 34.61-- ― ―
Price-to-Earnings Growth (PEG) Ratio
 114.36-- ― ―
Enterprise Value Multiple
 9.52-- ― ―
Enterprise Value
 12.31B 47.20B 46.31B ― ―
EV to EBITDA
 9.54 50.49 24.42 ― ―
EV to Sales
 0.48 1.84 2.62 ― ―
EV to Free Cash Flow
 6.40 24.56 53.31 ― ―
EV to Operating Cash Flow
 6.40 24.56 32.57 ― ―
Tangible Book Value Per Share
 3.91-- ― ―
Shareholders’ Equity Per Share
 2.16-- ― ―
Tax and Other Ratios
Effective Tax Rate
 0.22-- ― ―
Revenue Per Share
 9.42-- ― ―
Net Income Per Share
 0.28-- ― ―
Tax Burden
 0.78 0.78 0.75 ― ―
Interest Burden
 0.76 0.76 0.75 ― ―
Research & Development to Revenue
 0.00 0.00 0.00 ― ―
SG&A to Revenue
 0.02 0.02 0.02 ― ―
Stock-Based Compensation to Revenue
 0.00 0.00 0.00 ― ―
Income Quality
 4.64 4.64 4.99 ― ―
Currency in CNY